Protecting the Golden Age of Medicine with John Crowley
Jul 23, 2024
auto_awesome
John Crowley, President and CEO of BIO, shares his personal journey into biotech driven by his children's Pompe disease. They discuss navigating policies in medicine, developing treatments, rising costs of genetic medicines, and securing the medicine supply chain for national security.
John Crowley's relentless pursuit of developing a treatment for Pompe disease showcases his resilience and dedication in the face of adversity.
Securing funding through unconventional means and strategic decisions propelled John Crowley's success in the biotechnology industry.
Deep dives
The Journey into Biotechnology Industry
John Crowley's entry into the biotechnology industry was sparked by his daughter's diagnosis with Pompe disease, a rare form of muscular dystrophy. Determined to find a treatment, he embarked on the path of researching and connecting with experts. Crowley's relentless pursuit led to the establishment of a company focused on developing a therapy for Pompe disease, showcasing his resilience and dedication in the face of adversity.
Challenges and Success in Building Biotech Companies
Facing considerable financial obstacles, John Crowley managed to secure funding through unconventional means, like a home equity loan and credit card advances, to advance his biotech endeavors. Despite numerous setbacks, including his daughter's health deterioration, Crowley's commitment and strategic decisions enabled the successful sale of his first company for over $100 million, laying the foundation for further contributions to the field.
Shaping the Future of Biotechnology Innovation
Transitioning from leading biotech companies to helming the Biotechnology Innovation Organization (BIO), John Crowley embraces the mission of fostering innovation and access in the industry. Advocating for patient-centered policies and addressing challenges in drug pricing and supply chain security, Crowley underscores the industry's transformative potential in advancing personalized medicine and scientific breakthroughs for global health.
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joined Jorge Conde, general partner at a16z Bio + Health.
Together, they talk about John’s entry into biotech and his time as a founder, all motivated by his determination to discover and develop a treatment for his children, who have Pompe disease.
They also talk about John’s priorities as head of BIO and how that could translate into policy.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode